Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer

23 Apr 2025

Abstract excerpt

Exquisitely chemosensitive initially, small cell lung cancer (SCLC) exhibits dismal outcomes owing to rapid transition to chemoresistance. Elucidating the genetic underpinnings has been challenging owing to limitations with cellular models. As SCLC patient-derived xenograft (PDX) models mimic therapeutic responses, we perform genetic screens in chemosensitive PDX models to identify drivers of chemoresistance....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40267200
DOI: 10.1126/sciadv.adq7084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancerPMID 40267200Read ↗

Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.Semantic proximity Read ↗

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerSemantic proximity Read ↗

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerSemantic proximity Read ↗

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read ↗

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.Semantic proximity Read ↗

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activationSemantic proximity Read ↗

A multiplexed in vivo approach to identify driver genes in small cell lung cancerSemantic proximity Read ↗

FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancerSemantic proximity Read ↗

KDM6B Inhibition Enhances Chemotherapeutic Response in Small Cell Lung Cancer via Epigenetic Regulation of Apoptosis and FerroptosisSemantic proximity Read ↗

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Semantic proximity Read ↗

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung AdenocarcinomaSemantic proximity Read ↗

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenograftsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.